Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1

Conditions

Carcinoma, Renal Cell 32Sarcoma 29Neoplasm Metastasis 17Ovarian Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Kidney Neoplasms 6Recurrence 5Lung Neoplasms 5Liposarcoma 5Thyroid Neoplasms 4Melanoma 4Leiomyosarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Pancreatic Neoplasms 3Neurofibrosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Chondrosarcoma, Extraskeletal Myxoid 3Advanced Cancers 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Recurrence × pazopanib × Clear all
NCT06816771 2025-02-10

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma

NCT02203760 2024-11-15

PazoDoble

North Eastern German Society of Gynaecological Oncology

Phase 2 Active not recruiting
58 enrolled
Sarcoma

Carcinosarcoma, Leiomyosarcoma, Recurrence

NCT01610206 2021-02-25

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

University of Virginia

Phase 2 Completed
148 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01713296 2015-10-08

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

Hellenic Oncology Research Group

Phase 2 Completed
58 enrolled

Recurrence

NCT01165385 2014-11-17

PACIFIK

UNICANCER

Phase 1 Completed
35 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡